Our Resources | Association for Accessible Medicines

2023 The U.S. Generic & Biosimilar Medicines Savings Report

Sep 6, 2023 | Monét Stanford

Report: 2023 U.S. Generic and Biosimilar Medicines Savings Report

AAM - Your Generics & Biosimilars Industry

Jun 22, 2023 | Erica Klinger

AAM White Paper on Shortages

2022 2022 U.S Generic and Biosimilar Medicines Savings Report

Sep 21, 2022 | Erica Klinger

Report: 2022 U.S. Generic and Biosimilar Medicines Savings Report

Jun 13, 2022 | Erica Klinger

AAM Code of Business Ethics

AAM Voices of Access

Feb 10, 2022 | Dan Leonard

AAM Voices of Access 2022

2021 U.S. Generic and Biosimilar Medicines Savings Report

Oct 12, 2021 | Erica Klinger

Report: 2021 U.S. Generic and Biosimilar Medicines Savings Report

New Evidence Shows Medicare Part D Plans Continue to Fail to Get New Generics to Seniors

Jul 13, 2021 | Erica Klinger

New Evidence Shows Medicare Part D Plans Continue to Fail to Get New Generics to Seniors

AAM Patients - Voices of Access

May 24, 2021 | Erica Klinger

AAM Voices of Access

Roadmaps for Ensuring Patient Access to Generic and Biosimilar Medicines: Securing Sustainable Markets

Feb 22, 2021 | Erica Klinger

Roadmaps for Ensuring Patient Access to Generic and Biosimilar Medicines: Securing Sustainable Markets

Potential Savings from Accelerating US Approval of Complex Generics

Feb 9, 2021 | Erica Klinger

White Paper: Potential Savings from Accelerating U.S. Approval of Complex Generics

Nitrosamines: An Industry Position Paper Based on Risk

Oct 6, 2020 | Erica Klinger

White Paper: Nitrosamines — An Industry Position Paper Based on Risk

2020 Generic Drug and Biosimilars Access & Savings in the U.S. Report - Cover image

Sep 29, 2020 | Erica Klinger

2020 Generic Drug & Biosimilars Access and Savings in the U.S. Report